Munck, L. de

cancer patient margin hospital treatment group breast docetaxel margin status study group b toxicity tumor case mix correction netherland status breast cancer surgery percentage breast cancer patients table signi ficant quality number result ef ficacy signi response target ficacy correction limit metastatic schedule analysis agreement difference fi rst bcs fi rst surgery dutch oncol progression indicator metastatic breast cancer phase survival disease neutropenia information value multivariate breast-conserving ficant proportion course oncology variation cancer 4 7 1.3 dose intensity duration european risk factors factor quality indicator randomised p-value treatment discontinuation carcinoma 10 hospitals characteristic target value guideline arm b breast-conserving surgery ductal surgeon breast cancer care classi administration